Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Théberge, J. Articles by Williamson, P. C. Search for Related Content PubMed Citation Articles by Théberge, J. Articles by Williamson, P. C. Neuroendocrinology Schizophrenia Spectrum Disorders MRS Neurodegeneration

Glutamate and Glutamine Measured With 4.0 T Proton MRS in Never-Treated Patients With Schizophrenia and Healthy Volunteers

OBJECTIVE: This in vivo ¹H magnetic resonance spectroscopy study examined levels of glutamate, glutamine, and N-acetylaspartate in patients experiencing their first episode of schizophrenia. METHOD: Localized in vivo ¹H spectra were acquired at 4.0 T from the left anterior cingulate and thalamus of 21 never-treated patients with schizophrenia and 21 comparable healthy volunteers. RESULTS: The level of glutamine was significantly higher in the left anterior cingulate cortex and thalamus of the patients with schizophrenia than in the healthy subjects. No differences were found between groups in the levels of other metabolites in the anterior cingulate or thalamus. CONCLUSIONS: Higher than normal glutamine levels in the left anterior cingulate and thalamus provide in vivo evidence of greater than normal glutamatergic activity proposed by glutamatergic models of schizophrenia. In contrast to other studies in chronically ill patients, no differences were seen in the levels of N-acetylaspartate in either location, suggesting that the findings in patients with chronic schizophrenia may be related to the effect of medication or the progression of the illness.

This article has been cited by other articles:

				A. Fornito, M. Yucel, B. Dean, S. J. Wood, and C. Pantelis Anatomical Abnormalities of the Anterior Cingulate Cortex in Schizophrenia: Bridging the Gap Between Neuroimaging and Neuropathology Schizophr Bull, September 1, 2009; 35(5): 973 - 993. [Abstract] [Full Text] [PDF]

				H. van Wageningen, H. A. Jorgensen, K. Specht, and K. Hugdahl A 1H-MR Spectroscopy Study of Changes in Glutamate and Glutamine (Glx) Concentrations in Frontal Spectra after Administration of Memantine Cereb Cortex, July 15, 2009; (2009) bhp145v1. [Abstract] [Full Text] [PDF]

				J. A. Lieberman, F. P. Bymaster, H. Y. Meltzer, A. Y. Deutch, G. E. Duncan, C. E. Marx, J. R. Aprille, D. S. Dwyer, X.-M. Li, S. P. Mahadik, et al. Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection Pharmacol. Rev., September 1, 2008; 60(3): 358 - 403. [Abstract] [Full Text] [PDF]

				J. F. W. Deakin, J. Lees, S. McKie, J. E. C. Hallak, S. R. Williams, and S. M. Dursun Glutamate and the Neural Basis of the Subjective Effects of Ketamine: A Pharmaco-Magnetic Resonance Imaging Study Arch Gen Psychiatry, February 1, 2008; 65(2): 154 - 164. [Abstract] [Full Text] [PDF]

				J. THEBERGE, K. E. WILLIAMSON, N. AOYAMA, D. J. DROST, R. MANCHANDA, A. K. MALLA, S. NORTHCOTT, R. S. MENON, R. W. J. NEUFELD, N. RAJAKUMAR, et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia The British Journal of Psychiatry, October 1, 2007; 191(4): 325 - 334. [Abstract] [Full Text] [PDF]

				J. M. Stone, P. D. Morrison, and L. S. Pilowsky Review: Glutamate and dopamine dysregulation in schizophrenia a synthesis and selective review J Psychopharmacol, June 1, 2007; 21(4): 440 - 452. [Abstract] [PDF]

				M. S. KESHAVAN, G. BERGER, R. B. ZIPURSKY, S. J. WOOD, and C. PANTELIS Neurobiology of early psychosis The British Journal of Psychiatry, August 1, 2005; 187(48): s8 - s18. [Abstract] [Full Text] [PDF]

				L. M. Rowland, J. R. Bustillo, P. G. Mullins, R. E. Jung, R. Lenroot, E. Landgraf, R. Barrow, R. Yeo, J. Lauriello, and W. M. Brooks Effects of Ketamine on Anterior Cingulate Glutamate Metabolism in Healthy Humans: A 4-T Proton MRS Study Am J Psychiatry, February 1, 2005; 162(2): 394 - 396. [Abstract] [Full Text] [PDF]

				G. S. J. Rands, J. E. Jensen, J. Miller, P. C. Williamson, R. W. J. Neufeld, R. S. Menon, A. Malla, R. Manchanda, B. Schaefer, M. Densmore, et al. Memantine as a neuroprotective treatment in schizophrenia * Authors' reply The British Journal of Psychiatry, January 1, 2005; 186(1): 77 - 78. [Full Text] [PDF]

				P. Tibbo, C. Hanstock, A. Valiakalayil, and P. Allen 3-T Proton MRS Investigation of Glutamate and Glutamine in Adolescents at High Genetic Risk for Schizophrenia Am J Psychiatry, June 1, 2004; 161(6): 1116 - 1118. [Abstract] [Full Text] [PDF]

				J. E. Jensen, J. Miller, P. C. Williamson, R. W. J. Neufeld, R. S. Menon, A. Malla, R. Manchanda, B. Schaefer, M. Densmore, and D. J. Drost Focal changes in brain energy and phospholipid metabolism in first-episode schizophrenia: 31P-MRS chemical shift imaging study at 4 Tesla The British Journal of Psychiatry, May 1, 2004; 184(5): 409 - 415. [Abstract] [Full Text] [PDF]

				J. Theberge, Y. Al-Semaan, P. C. Williamson, R. S. Menon, R. W.J. Neufeld, N. Rajakumar, B. Schaefer, M. Densmore, and D. J. Drost Glutamate and Glutamine in the Anterior Cingulate and Thalamus of Medicated Patients With Chronic Schizophrenia and Healthy Comparison Subjects Measured With 4.0-T Proton MRS Am J Psychiatry, December 1, 2003; 160(12): 2231 - 2233. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us